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Abstract: Aptamers, single stranded DNA or RNA molecules, generated by a method called 
SELEX (systematic evolution of ligands by exponential enrichment) have been widely used 
in various biomedical applications. The newly developed Cell-SELEX (cell based-SELEX) 
targeting whole living cells has raised great expectations for cancer biology, -therapy and 
regenerative medicine. Combining nanobiotechnology with aptamers, this technology opens 
the way to more sophisticated applications in molecular diagnosis. This paper gives a 
review of recent developments in SELEX technologies and new applications of aptamers. 
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1. Introduction  
SELEX (systematic evolution of ligands by exponential enrichment) is a method to generate DNA 
or RNA ligands from a combinatorial library. This oligonucleotide library consists of single stranded 
modified or unmodified RNA or DNA. The ligands that emerge from SELEX have been called 
aptamers [1]. Aptamers have promising advantages compared to antibodies: they can be produced 
easily and inexpensively and are simple to chemically modify and integrate into different analytical 
schemes. Aptamers can retain their binding and inhibitory behavior after immobilization on a carrier 
material [2] or after delivery into animals [3] and can be labeled with various functional groups [4]. Int. J. Mol. Sci. 2008, 9                                 669 
 
 
These properties of aptamers have led to their application in many areas of biomedical sciences such as 
purification processes [5], target validation [6], drug development [7], diagnostics [8], MRI-based cell 
tracking [9] and even therapy [3].  
2.  SELEX methodology and clinical applications of aptamers 
The first SELEX experiments were performed in the 1990s by the independent research groups of 
Gold and Ellington [1, 10-11], proceeding typically as follows: First a combinatorial nucleic acid 
library (DNA or RNA) is synthesized. The sequence of the library is composed of random sequences 
in the middle and flanked by fixed sequences as primer binding sites. The length of the random region 
is normally between 20 to 40 bp, which creates a library with a large number of random sequences 
(10
15 to 10
16). The size of the library is large enough to saturate the relevant sequence space. The 
library is then incubated with the desired target molecule under conditions suitable for binding. Next, 
the unbound nucleic acids are partitioned from those bound specifically to the target molecule, which 
are then eluted from the target molecule and amplified by PCR. This selection procedure is reiterated 
for several rounds until the resulting sequences are highly enriched. The selected nucleic acids are 
subjected to DNA sequencing and screened for potential binding affinity. SELEX technology 
generates aptamers with high binding affinity and specificity. Their advantages have made them very 
promising in analytical, diagnostic and therapeutic applications [12-15].  
As small molecules , with a half-life of minutes to hours due to nuclease degradation, aptamers can 
be rapidly cleaned from the bloodstream by the kidneys. The applications of unmodified aptamers are 
mainly focused on treating transient conditions such as blood clotting [16-17], or treating organs, for 
example the eye where local delivery is possible [18-19]. This rapid clearance is an advantage in some 
applications such as in vivo diagnostic imaging, for example a tenascin-binding aptamer under 
development for cancer imaging [20]. There are several modifications available, such as 2'-fluorine-
substituted pyrimidines, polyethylene glycol (PEG) linkage, etc. (both of which are used in Macugen, 
an FDA-approved aptamer), that can increase the half-life of aptamers easily to a day or even a week 
[21-22].  
The first aptamer approved for use in man is a RNA-based molecule (Macugen, Pegaptanib) that is 
administered locally to treat age-related macular degeneration by targeting vascular endothelial growth 
factor (VEGF). Pegaptanib is a pegylated anti-VEGF aptamer, a single stranded nucleic acid that binds 
with high specificity to a particular target. Pegaptanib specifically binds to VEGF165, a protein that 
plays a critical role in angiogenesis (the formation of new blood vessels) and in increased permeability 
(leakage from blood vessels), two of the primary pathological processes responsible for the vision loss 
associated with AMD (age-related macular degeneration). The brand name Macugen for Pegaptanib 
denotes an anti-angiogenic medicine for the treatment of neovascular (wet) AMD. FDA-approval was 
granted in December 2004 [23-24].  
The most advanced aptamer in the cancer setting is AS1411, formerly known as AGRO100, which is 
being administered systemically in clinical trials [25]. AS1411 is a 26-mer unmodified guanosine-rich 
oligonucleotide, which induces growth inhibition in vitro, and has shown activity against human tumor 
xenografts in vivo. The mechanism underlying its antiproliferative effects in cancer cells seems to 
involve initial binding to cell surface nucleolin and internalization, leading to an inhibition of DNA Int. J. Mol. Sci. 2008, 9                                 670 
 
 
replication. In contrast to other unmodified oligonucleotides, AS1411 is relatively stable in serum-
containing medium through the formation of dimers and a quartet structure. In a dose escalation phase 
I study in patients with advanced solid tumors, doses up to 10 mg/kg/d (using a four or seven 
continuous infusion regime) have been tested [26]. Promising signs of activity were reported (multiple 
cases of stable disease and one near complete response in a patient with renal cancer) in the absence of 
any significant adverse effects. Further trials are ongoing in renal and non–small cell lung cancers 
[27]., Additional aptamers have been described in preclinical studies against several cancer targets, 
such as the antiapoptotic, the transcription factor signal transducer and activator of transcription 3, and 
the Ku proteins [28]. Apoptosis is an essential cellular process critical for tissue homeostasis and 
animal development in metazoans. Abnormal inactivation of apoptosis can result in uncontrolled cell 
growth, leading to development of cancer and autoimmune disorders. The human proto-oncogene bcl-
2 controls apoptosis by an evolutionarily conserved cell death pathway. Members of this family can be 
either antiapoptotic or proapoptotic and can form heterodimers with other selected family members to 
affect apoptosis. CED-9 is a cell death inhibitor and a homologue of human Bcl-2. Developing 
effective therapeutic methods to correct or reverse inappropriate apoptosis is a critical issue in clinical 
medicine. Aptamers have been successfully generated to antagonize the prosurvival activity of CED-9 
and kill cells through the normally programmed cell death pathway. These results suggest that RNA 
aptamers for key cell death regulators can yield, or serve as leads, to generate potent compounds that 
modulate apoptosis in vivo [29-31]. The transcription factor signal transducer and activator of 
transcription (Stat3) plays an essential role in embryonic development and assumes specialized tasks in 
many differentiated tissues. Constitutively activated Stat3 has been found in tumor cell lines and 
primary tumors and plays a crucial role in tumor cell survival and proliferation [32]. The peptide 
aptamers that have been generated to inhibit the oncogenic action of Stat3 in tumor cells, can 
recognize the Stat3 DNA binding domain and inhibit DNA binding and transactivation by Stat3 
following EGF stimulation of cells.  Inhibiting the Stat3 functions through  interaction with peptide 
aptamers counteracts the transformed phenotype and could become useful in targeted tumor therapy 
[33].  
2.1. Cell-SELEX 
A modification of the traditional SELEX process that uses whole living cells as target  was named 
cell-SELEX (Figure 1). Aptamers with high affinity and specificity for cells have been produced 
successfully, demonstrating that complex targets, including tumor cells and tissues, are compatible 
with the SELEX process [34]. Using purified proteins as targets has the obvious advantage of easy 
control to achieve optimal enrichment during the selection process. But Cell-SELEX is favored in 
some special cases, when the clear marker target is unknown. Furthermore, since the target protein 
domain may be shielded and inaccessible on a cell surface, it reflects a more physiological condition 
when the protein is displayed on the cell surface rather than isolated as purified protein., 
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Figure 1.  Cell-SELEX procedure. In the Cell-SELEX procedure, the target for SELEX 
is whole living cells. In this case, aptamers bind with the membrane protein of the cells. 
The selection of aptamer is cyclically repeating, during selection rounds the binding 
affinity can be controlled by Flow cytometry assay to decide the end of selection. 
The whole cell selection process is easy to handle, fast and reproducible. It makes aptamers an 
effective tool for molecular medicine and biomarker discovery. In recent reports, the Cell-SELEX 
technology plays an important role in cancer biology. For most cancer cells, there is always a shortage 
of high specific surface markers for diagnosis and therapy. Aptamers generated from whole living cells 
are the optimal molecular probe to characterize target cells on a molecular level. When bound with the 
membrane receptors of the cell lines, they provide an effective approach for the discovery of 
biomarkers as disease signals. The development of aptamer probes for molecular signatures on the 
cancer cell surface is highly specific, allows defining of tumors, and creates an opportunity for more 
‘personalized’ treatment. The generation of aptamers to normal cells and cancer cells enables a 
comparative strategy to identify differences at a molecular level and to promote the discovery of 
molecular features of cancer cells. 
The advantages of whole living Cell-SELEX-based aptamers facilitate the development of and 
simplify the search for molecular probes for diseased cell recognition [35-37]. Aptamers can also be 
used for the recognition of differences at a molecular level between any two given populations of cells, 
such as tumor cell type 1 vs. type 2. These differences possess great significance in aiding the 
understanding of the biological processes and mechanisms of diseases. It is difficult to identify the 
molecular differences and validate them specifically with current technology.  Tang et al. [38] 
developed aptamers for the specific recognition of Burkitt’s lymphoma cells. Burkitt’s lymphoma, an 
acute blood cell cancer, is one of the most progressive human cancers. Early diagnosis and targeted 
therapy are crucial for patient treatment. However, the lack of effective molecular probes to recognize 
Start library 1015
Oligonucleotide
Target cells incubation
Unbound 
sequences 
Incubation with target cells and 
non-target cells
Amplified library 
for next round 
selection
Unbound 
sequences  Selection and counter selection
Repeat the 
selection for 8-10 
rounds.
Final selected 
sequence
incubation
Clone and 
sequencing
Start library 1015
Oligonucleotide
Target cells incubation
Unbound 
sequences 
Incubation with target cells and 
non-target cells
Amplified library 
for next round 
selection
Unbound 
sequences  Selection and counter selection
Repeat the 
selection for 8-10 
rounds.
Final selected 
sequence
incubation
Clone and 
sequencingInt. J. Mol. Sci. 2008, 9                                 672 
 
 
cell surface biomarkers prevents early diagnosis of Burkitt’s lymphoma and makes the study of its 
developing mechanism difficult if not impossible. Of the many possible probes, aptamers hold the 
greatest potential in molecular recognition and targeting. The generated aptamers showed excellent 
specificity and strong affinity for Ramos cells, a Burkitt’s lymphoma cell line. The selected probes are 
very helpful for understanding the molecular interactions and recognition events on Ramos cells, as 
well as for the future medical diagnosis and treatment of lymphoma. Tumor Cell-SELEX also 
demonstrates the ability of aptamers to identify known tumor markers, such as tenascin-C [21]. 
Tenascin-C is an extracellular matrix protein that is overexpressed during tissue remodeling processes, 
including tumor growth. It is believed to be a stromal marker for epithelial malignancy [39]. TTA1, an 
aptamer against the extracellular matrix protein tenascin-C, can be taken up by a variety of solid 
tumors including breast, glioblastoma, lung, and colon. Rapid uptake by tumors and fast clearance 
from the blood and other non-target tissues enables clear tumor imaging. This aptamer shows high 
potential for in vivo delivery of radioisotopes or cytotoxic agents [20]. Cerchia et al. adopted a whole-
cell-SELEX strategy to target RET receptor (rearranged during transfection) in a complex environment 
that was expected to expose a native protein to the selection procedure, thus best mimicking in vivo 
conditions. Nuclease-resistant aptamers, that can recognize the human receptor tyrosine kinase RET, 
were obtained using RET-expressing cells as targets in a modified SELEX procedure [40]. The 
aptamers also blocked RET downstream signaling and subsequent molecular and cellular events. The 
fact that aptamers with anti-oncogenic activity were isolated in the absence of a specific selective 
pressure, suggests that the method could be used to identify active macromolecules with high potential 
therapeutic interest against other transmembrane receptors. Guo et al. generated aptamers for the 
isolation of mesenchymal stem cells from whole bone marrow [41]. The isolated MSCs can be used 
directly for local injection or other applications. When bound to magnetic particles aptamers could be 
used for stem cell tracking [9]. Furthermore, they found, after immobilizing aptamers against 
osteoblasts on titanium [42], that aptamer-coated titanium surfaces can enrich osteoblasts quickly and 
efficiently. This fast and highly efficient method based on aptamers will bring novel aspects of MSCs 
to the field of regenerative medicine and tissue engineering. 
3. Aptamers and nanobiotechnology 
The term ‘nanotechnology’ is defined as the processing of separation, consolidation, and 
deformation of materials by one atom or one molecule, and includes the understanding and control of 
matter at dimensions of 1-100nm where unique phenomena enable novel applications. The bulk 
physical properties of materials often become very different when broken down at nano-scale; 
therefore, nanotechnology generates new opportunities and applications. Nanomaterials and devices 
provide unique opportunities to advance medicine referred to as ‘nanomedicine’, which impact 
diagnosis, monitoring and treatment of diseases as well as control and understanding of biological 
systems [43]. Applying nanotechnology to the aptamer field, Tan et al. have successfully constructed 
an aptamer-conjugated nanoparticle for the collection and detection of multiple cancer cells [44]. They 
attached aptamers to magnetic nanoparticles (MNP) and fluorescent nanoparticles (FNP) to develop a 
specific platform for collecting and imaging intact leukemia cells from mixed cell- and whole blood 
samples. Furthermore, they developed an aptamer-conjugated nanoparticles protocol to perform the Int. J. Mol. Sci. 2008, 9                                 673 
 
 
extraction of multiple cancer cell targets using additional high-affinity aptamers for recognition. They 
utilized 65nm silica-coated MNP instead of the traditional micrometer-sized magnetic polymer beads. 
The small size and relatively high surface area of NPs provide enhanced extraction capabilities and 
eliminate the need for pre-sample cleanup. Upon excitation, the FNP conjugated aptamer can produce 
significantly higher signal intensity and -stability than other individual dye probes. The method of 
conjugating aptamers with nanoparticles has the potential to be  used in profiling applications with 
furhter development of aptamer technology [45].  
Another new application is to fabricate electrochemical aptamers as molecular recognition elements 
for nanoscale biosensors. Taking advantage of small size aptamers from 10-60 bp in length, the 
binding with target molecules can occur inside the electrical double layer and in saline solution. By 
using aptamers for recognition, no labeling is required for electrochemical sensors, and signal-on 
architecture that is only possible with aptamers, has improved their sensitivity. The sensors can be 
recycled because of the reversibility of aptamer configurations. Alternatively, bound proteins may 
simply be washed off without damaging the aptamers. Aptamers have already proven to be superior to 
antibodies in nanosensors [46-49]. 
Aptamer-conjugated nanoparticles for drug delivery to treat cancer cells come up as another new 
and exciting application. One of the biggest issues with current cancer therapies is that most of them 
kill both healthy and cancerous cells. Drug delivery specialists are now presented with the challenge 
and the opportunity to increase the therapeutic index and ultimately deliver targeted therapies to cancer 
cells while minimizing off-target side effects. These bioconjugates represent an exciting prospect in 
the advancing field of cancer nanotechonology and hold significant promise for future cancer 
treatment. By modifying the controlled-release polymer system or tweaking the aptamer targeting 
group it may be possible to produce a diverse range of specific and selective bioconjugates (Figure 2). 
In this way, drug delivery 'vehicles' could target numerous significant human cancers. The application 
of nanotechnology to cancer therapy is expected to result in future therapeutic modalities that are 
superior to our current approach. Most importantly, this is no longer farfetched science: nanoscale 
drug delivery vehicles are already getting closer to clinical realization. 
4. Aptamers and gene silencing 
When conjugated to aptamers, the mediate targeted delivery of small interfering RNAs (siRNAs) 
can be greatly improved resulting in higher therapeutic efficacy and safety [50-51]. This approach has 
the advantage that therapeutics can be composed entirely of RNA. The aptamer-siRNA chimeric 
RNAs are capable of cell type-specific binding and delivery of functional siRNAs into cells [52]. For 
example, the aptamer portion of the chimeras mediates binding to PSMA (prostate-specific membrane 
antigen), a cell-surface receptor overexpressed in prostate cancer cells and tumor vascular 
endothelium, whereas the siRNA portion targets the expression of survival genes. When applied to 
cells expressing PSMA, these RNAs are internalized and processed by Dicer, resulting in depletion of 
the siRNA target proteins and cell death. In contrast, the chimeras do not bind to or function in cells 
that do not express PSMA. These reagents also specifically inhibit tumor growth and mediate tumor 
regression in a xenograft model of prostate cancer [53]. These studies demonstrate a novel approach 
for targeted delivery of siRNAs with numerous potential applications, including cancer therapeutics. Int. J. Mol. Sci. 2008, 9                                 674 
 
 
Short aptamers (25–35bp) have been generated that bind to a wide variety of targets with a high 
affinity. It should be possible to design siRNA-aptamer chimeras with longer strands (45–55bp) that 
are within the range of technical and commercial feasibility for synthesis,  however, molecules longer 
than that may be difficult to synthesize on a commercial scale. Although short aptamer-conjugates 
work for local delivery in vivo, they are rapidly cleared by the kidney and have a half-life too short for 
systemic therapy unless they are incorporated into larger particles. 
Figure 2. Apatamer-conjugated nanoparticle for delivery of drugs to treat cancer. 
The aptamer-conjugated nanoparticle acts as a drug delivery 'vehicle', first the aptamer 
finds the cancer cell and binds it, then the nanoparticle can release the drug molecules to 
kill the cancer cell.  
5. Conclusion 
The encouraging results obtained by aptamers based on their intrinsic properties and the versatility 
of the SELEX procedure generates new applications in diagnostic as well as therapeutic fields. The 
ability to discriminate between two closely related targets, for example a cancerous cell and an 
untransformed cell of the same tissue type, makes aptamers suitable as imaging reagents for non-
invasive diagnostic procedures. Even though the combined use of aptamers with nanoparticles is still a 
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novel concept, a growing number of valuable results have been reported contributing to cancer 
medicine and molecular medicine and opening up a huge potential for numerous clinical applications. 
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